Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of R-406. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK known ✓ | P43405 | 14/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | TYRO3 | Q06418 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | STK16 | O75716 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 2/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 2/20 | 1.00 |
| ▸ | MST1R | Q04912 | 2/20 | 1.00 |
| ▸ | TNK1 | Q13470 | 2/20 | 1.00 |
| ▸ | IKBKE | Q14164 | 2/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 1.00 |
| ▸ | ADCK1 | Q86TW2 | 2/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 1.00 |
| ▸ | NEK9 | Q8TD19 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | IRAK3 | Q9Y616 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-406 SCHEMBL1200144 | 1.00 | SYK (1.00) | SYKPTK2AURKAADORA3TYRO3 | |
| R-406 SCHEMBL12903997 | 0.96 | SYK (0.92) | SYKPTK2AURKAADORA3TYRO3 | |
| R-406 SCHEMBL12903982 | 0.95 | SYK (0.91) | SYKPTK2AURKAADORA3TYRO3 | |
| SCHEMBL2627469 | 0.95 | SYK (0.91) | SYKPTK2AURKAADORA3TYRO3 | |
| SCHEMBL1383686 | 0.94 | SYK (0.89) | SYKPTK2AURKAADORA3TYRO3 | |
| R-406 SCHEMBL12904000 | 0.94 | SYK (0.89) | SYKPTK2AURKAADORA3TYRO3 | |
| SCHEMBL11937326 | 0.93 | SYK (0.87) | SYKPTK2AURKAADORA3TYRO3 | |
| R-406 SCHEMBL12903973 | 0.93 | SYK (0.86) | SYKPTK2AURKAADORA3TYRO3 | |
| R-406 SCHEMBL12904025 | 0.92 | SYK (0.84) | SYKPTK2AURKAADORA3TYRO3 | |
| R-406 SCHEMBL1222514 | 0.91 | ADORA3 (1.00) | SYKPTK2AURKAADORA3TYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-12534472-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-27 | — | — | US | disclosed |
| US-20260014160-A1 | G1T38 SUPERIOR DOSAGE REGIMES | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-15 | — | — | US | disclosed |
| EP-4665720-A2 | ISOINDOLINONE GLUTARIMIDE AND PHENYL GLUTARIMIDE ANALOGS AS DEGRADERS OF RET KINASE | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12454521-B2 | Targeted protein degradation | C4 THERAPEUTICS, INC. | 2025-10-28 | — | — | US | disclosed |
| US-12454539-B2 | Controlled-delivery cromakalim prodrugs | QLARIS BIO, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4611901-A1 | RET-LDD PROTEIN DEGRADERS | Bristol-Myers Squibb Company (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4013420-A1 | METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME | Rigel Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220175780-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | PHARMACOSMOS A/S (DK) | 2022-06-09 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022032132-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014160-A1 | G1T38 SUPERIOR DOSAGE REGIMES | CDK4, CCND1, CDK8 | SYK 301/4885PTK2 714/4885AURKA 201/4885 |
| US-20220175780-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | RB1, CDK4, CDK6 | SYK 2925/4885PTK2 2033/4885AURKA 127/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | SYK 3247/4885PTK2 3814/4885AURKA 3641/4885 |
| US-12454521-B2 | Targeted protein degradation | STUB1, MDM2, UBE3A | SYK 2617/4885PTK2 2892/4885AURKA 733/4885 |
| US-12454539-B2 | Controlled-delivery cromakalim prodrugs | KCNJ1, KCNJ8, KCNJ11 | SYK 2892/4885PTK2 1489/4885AURKA 567/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | SYK 3539/4885PTK2 2113/4885AURKA 907/4885 |
| US-12534472-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | CTNND1, FLT3, MEF2D | SYK 313/4885PTK2 316/4885AURKA 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.